

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

A ONE-STEP SYNTHESIS OF CLOMID INTERMEDIATE

Mohammed I. Al-Hassan^a

^a Department of Chemistry College of Science, King Saud University, Saudi Arabia

To cite this Article Al-Hassan, Mohammed I.(1991) 'A ONE-STEP SYNTHESIS OF CLOMID INTERMEDIATE', Organic Preparations and Procedures International, 23: 1, 116 – 118

To link to this Article: DOI: 10.1080/00304949109458292

URL: <http://dx.doi.org/10.1080/00304949109458292>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.


The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

A ONE-STEP SYNTHESIS OF CLOMID INTERMEDIATE

Submitted by
(11/06/89)

Mohammed I. Al-Hassan
Department of Chemistry
College of Science, King Saud University
P. O. Box 2455, SAUDI ARABIA

Clomiphene citrate (Clomid), a mixture of the citrate salt of E- and Z-isomers of N,N-diethyl-2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]ethanamine (1), is one of the most common drugs used for the treatment of infertility; it is used to induce ovulation and hence promote fertility in anovulatory women who have functional ovaries and adenohipophysis. Clomid acts directly on the hormone regulatory process in the brain to cause increased pituitary hormone release which in turn triggers ovulation.¹ Clomid is an expensive drug, due in part to the difficulty in preparing it.² This paper reports a short method for the preparation of a key clomid intermediate 2. Compound 2 could be obtained by hydroalumination of diphenylacetylene followed by C-C cross-coupling of the resulting vinylalane with the aryl bromide³ using catalytic amount of tetrakis(triphenylphosphine)palladium (60% yield) and by direct palladium-catalyzed cross-coupling of vinyl bromide⁴ with arylzinc chloride (70% yield). This direct cross-coupling failed in the past⁵ because of the difficulty in obtaining the corresponding arylzinc chloride. This problem has been resolved by treatment of one equivalent of 4-[2-(diethylamino)ethoxy]phenyl bromide with magnesium in the presence of two equivalents of ethylene dibromide which was added in small portions over 3 hrs to facilitate formation of Grignard reagent. The intermediate 2 could be transformed into clomid by treatment with N-chlorosuccinimide in chloroform, followed by treatment of the



- a) $i\text{-Bu}_2\text{AlH}$ b) $p\text{-(Et}_2\text{NCH}_2\text{CH}_2\text{O)C}_6\text{H}_4\text{Br}$, $(\text{Ph}_3\text{P})_4\text{Pd}$
c) $p\text{-(Et}_2\text{NCH}_2\text{CH}_2\text{O)C}_6\text{H}_4\text{ZnCl}$, $(\text{Ph}_3\text{P})_4\text{Pd}$

chlorinated product with equivalent amount of citric acid as previously described.² Compared to the published methods,² this route clearly is the shortest and most efficient known and appears to be promising for the synthesis of clomid and derivatives.

Though previously investigated, the stereochemistry of the hydroalumination⁴ and the cross-coupling⁶ is not important here (the chlorination step gives a mixture of E and Z isomers) because clomid is a mixture of isomers.

EXPERIMENTAL SECTION

Mps are uncorrected. IR spectra were recorded on a Beckman IR-8 spectrophotometer and calibrated against polystyrene. ¹H NMR spectra were obtained on JEOL JNM FX-100 spectrometer; chemical shifts are reported as δ values in part per million (ppm) downfield from internal TMS. Gpc analyses were performed on PYE Unicam series 304 chromatograph with OV1 glass column. Diisobutylaluminium hydride (Fluka) was used as 1M solution in hexane. All reactions were stirred magnetically and carried out under an atmosphere of nitrogen in oven-dried (160°) glassware. Tetrahydrofuran and hexane were distilled over sodium benzophenone ketyl. Other solvents were distilled and dried prior to use.

cis-1,2-Diphenyl-1-[4-(2-diethylaminoethoxy)phenyl]ethylene (2). Route A (via Palladium-catalyzed Cross-coupling of Vinylalane).- A solution of the vinylalane was prepared by the dropwise addition of 15 mL (15 mmol, 1.2 equiv) of 1M diisobutylaluminium hydride in hexane to 2.23 g (12.5 mmol, 1 equiv) of diphenylacetylene in 15 mL of hexane at 0°; it then was allowed to warm up with stirring to room temperature for 1 hr and then heated at 55° for 18 hrs and then cooled to room temperature.

To a separate flask containing tetrakis(triphenylphosphine)palladium (0.722 g, 0.625 mmol, 0.05 equiv) was added 4-[2-(diethylamino)ethoxy]phenyl bromide³ (3.1 g, 12.5 mmol, 1 equiv) in dry tetrahydrofuran (24 mL); this mixture was then added to the vinylalane solution prepared above. The reaction mixture was refluxed for 24 hrs. At the end of this time, the resulting mixture was cooled to room temperature and quenched with 40 ml water and thoroughly extracted with 3 x 60 ml of ether. The combined organic extracts were dried over anhydrous sodium sulfate. Evaporation of solvent and treatment of the crude product with hydrogen chloride gas followed by recrystallization (ethyl acetate-hexane) gave 3.05 g (60%) of the desired hydrochloride salt of 2 as a white crystalline solid, mp. 129-132°, lit.⁷ 137-140°; ¹H NMR (CDCl₃): δ 1.51 [m, 6H, (CH₃CH₂)₂], 3.33 [m, 4H, (CH₃CH₂)₂], 3.54 [m, 2H, NCH₂], 4.50 [m, 2H, -CH₂O] and 6.85-7.33 [m, 15H, aromatic H and vinyl H]. Comparison with an authentic sample⁷ gave superimposable spectra and a single peak upon co-injection by gpc (OV1 glass column).

Route B (via Palladium-catalyzed Cross-coupling of Vinyl Bromide).- A solution of 4-[2-(diethylamino)ethoxy]phenylzinc chloride was prepared by addition of the corresponding Grignard reagent [prepared by refluxing the corresponding aryl bromide (0.754 g, 3.1 mmol,

1 equiv) with magnesium (0.225 g, 9.3 mmol) in 45 ml THF; ethylene bromide (1.16 g, 6.17 mmol) was added in small portions over 3 hrs to facilitate formation of Grignard reagent] to a solution of anhydrous zinc chloride (0.42 g, 3.1 mmol, 1 equiv) in dry tetrahydrofuran (5 ml).

The resultant solution was refluxed for 30 min and then cooled to room temperature. To a separate flask containing tetrakis(triphenylphosphine)palladium (0.179 g, 0.155 mmol, 0.05 equiv) was added 1-bromo-1,2-diphenylethene (0.803 g, 3.1 mmol, 1 equiv) in dry tetrahydrofuran (5 mL); this mixture was then added to the arylzinc chloride solution prepared above. The reaction mixture was refluxed for 24 hrs, cooled to room temperature and worked-up as previously described. Evaporation of solvents and treatment of the crude product with hydrogen chloride followed by recrystallization (from ethyl acetate/hexane) gave 0.81 g (70% yield) of the desired hydrochloride salt. The ^1H NMR spectrum was identical to that reported above.

Acknowledgement.- The author is grateful to the King Abdulaziz City for Science and Technology (KACST) and to the Research Center, College of Science, King Saud University for financial support of this work. I also like to express my appreciation to Mr. M. M. Ahmad for technical assistance.

REFERENCES

1. S. Ernst and G. Hiti, *J. Pharm. Sci.*, **65**, 148 (1976); For reviews see R. J. Pepperell *et al.*, *Med. J. Aust.*, **2**, 774 (1977); D. G. Limb, *Practitioner*, **221**, 917 (1978), D. T. Baird, *Prescribers J.*, **19**, 99 (1979); F. Murad and R. C. Hagnes, "Estrogens and Progestin" in "The Pharmacological Basis of Therapeutics", Goodman and Gilman Eds, Macmillan, 6th Ed., p. 1420 (1980).
2. R. Allen *et al.*, U. S. Patent, 2,914,536 to Merrell (1959); M. Harper *et al.*, Brit. Patent, 1,064,629 (1967) to ICI; R. Shelton *et al.*, U. S. Patent, 2,430,891 (1947).
3. This compound was obtained by treatment of *p*-bromophenol with diethylaminoethyl chloride in the presence of sodium ethoxide, J. A. Katzenellenbogen and D. W. Robertson, *J. Org. Chem.*, **47**, 2387 (1982).
4. This compound was obtained *via* hydroalumination of diphenylacetylene or by bromination-dehydrobromination of stilbene; M. I. Al-Hassan, *Synth. Commun.*, **16**, 353 (1986).
5. M. I. Al-Hassan, *ibid.*, **17**, 1787 (1987).
6. M. I. Al-Hassan, *J. College of Science, KSU*, **18**, 103 (1987); E. Negishi, A. O. King and N. Okukado, *J. Org. Chem.*, **42**, 1821 (1977).
7. These samples were obtained from Merrell Co., Paris, France.